1. Efficacy and safety of Fuzheng Huayu tablet on persistent advanced liver fibrosis following 2 years entecavir treatment: A single arm clinical objective performance criteria trial
- Author
-
Zhi-Min Zhao, Chuan-Wu Zhu, Jia-Quan Huang, Xiao-Dong Li, Yu-Xi Zhang, Jian Liang, Wei Zhang, Yong Zhang, Xian-Gao Jiang, Ya-Li Zong, Ke-Jun Zhang, Ke-Wei Sun, Biao Zhang, Yun-Hai Lv, Hui-Chun Xing, Qing Xie, Ping Liu, and Cheng-Hai Liu
- Subjects
Pharmacology ,Liver Cirrhosis ,Hepatitis B virus ,Guanine ,Hepatitis B, Chronic ,Treatment Outcome ,Drug Discovery ,Humans ,Antiviral Agents ,Drugs, Chinese Herbal ,Tablets - Abstract
Antiviral therapy can alleviate liver fibrosis in chronic hepatitis B, but it has a limited effect on advanced liver fibrosis/cirrhosis. Traditional Chinese medicine (TCM), particularly FuZheng HuaYu (FZHY) tablet, appears to have an antifibrotic effect, but its improving resolution of hepatitis b virus (HBV) -associated advanced fibrosis and experienced anti-viral treatment has not been investigated.To observe the safety and efficacy of adjunctive FZHY on the HBV-associated cirrhosis patients who received 2 years of entecavir but still with advanced fibrosis.An open-label, multicentre, single arm trial. 251 patients were included and treated with TCM consisted of FZHY tablets 1.6 g and granules, three times a day in addition to entecavir 0.5 mg daily for an additional 48 weeks. Primary outcome was regression of fibrosis (the proportion of patients with a 1-point decrease in the Ishak liver fibrosis score from baseline to week 48).Fibrosis regression occurred in 94 of 184 patients with paired liver biopsy (51.09%, 95% CI: 43.9~58.0). In 132 compensated cirrhosis patients (Ishak score ≥5), 56.06% (74/132, 95% CI: 47.5~64.2) showed fibrosis regression and reached the goal of 54% (15% more than entecavir mono-therapy). 10 patients occurred adverse reaction, most of them were mild, and all recovered or achieved remission.The combination therapy of FZHY, TCM granules and ETV could regress the liver fibrosis in the patients with HBV cirrhosis, who experienced 2 years of ETV treatment, and it is safe and well tolerated.
- Published
- 2022